3-hydroxybutyric acid has been researched along with Diabetes Mellitus, Type 1 in 141 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ala and terbutaline produce sustained glucose recovery from hypoglycemia in IDDM and are therefore potentially useful agents for the treatment of mild or moderate iatrogenic hypoglycemia, or the prevention of iatrogenic hypoglycemia, when food intake is not anticipated over the following several hours." | 9.07 | Alanine and terbutaline in treatment of hypoglycemia in IDDM. ( Cryer, PE; Wiethop, BV, 1993) |
| "To investigate the relationship between leptin levels and IDDM with and without microalbuminuria, fasting serum levels of leptin, insulin, insulin-like growth factor-1 (IGF-1), sex hormone-binding globulin (SHBG), testosterone (SHBG) ratio, blood pressure and body mass index (BMI) were measured in 18 normo- and 11 microalbuminuric females with >5 years of IDDM, and 24 healthy controls in late puberty." | 7.70 | Serum leptin levels in young females with insulin-dependent diabetes and the relationship to hyperandrogenicity and microalbuminuria. ( Persson, B; Rudberg, S, 1998) |
| "In individuals with type 1 diabetes, hypoglycemia is a common consequence of overinsulinization." | 5.36 | Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. ( An, Z; Cherrington, AD; Farmer, B; Farmer, T; Irimia, JM; Lautz, M; Ramnanan, CJ; Rivera, N; Roach, PJ; Smith, M; Snead, W, 2010) |
| "Ala and terbutaline produce sustained glucose recovery from hypoglycemia in IDDM and are therefore potentially useful agents for the treatment of mild or moderate iatrogenic hypoglycemia, or the prevention of iatrogenic hypoglycemia, when food intake is not anticipated over the following several hours." | 5.07 | Alanine and terbutaline in treatment of hypoglycemia in IDDM. ( Cryer, PE; Wiethop, BV, 1993) |
| "Leptin can reverse hyperglycemia in rodent models of type 1 diabetes." | 3.83 | Insulin Knockout Mice Have Extended Survival but Volatile Blood Glucose Levels on Leptin Therapy. ( Covey, SD; Denroche, HC; Kieffer, TJ; Mojibian, M; Neumann, UH, 2016) |
| "To investigate the relationship between leptin levels and IDDM with and without microalbuminuria, fasting serum levels of leptin, insulin, insulin-like growth factor-1 (IGF-1), sex hormone-binding globulin (SHBG), testosterone (SHBG) ratio, blood pressure and body mass index (BMI) were measured in 18 normo- and 11 microalbuminuric females with >5 years of IDDM, and 24 healthy controls in late puberty." | 3.70 | Serum leptin levels in young females with insulin-dependent diabetes and the relationship to hyperandrogenicity and microalbuminuria. ( Persson, B; Rudberg, S, 1998) |
| "Rather than during illness while diabetic ketoacidosis (DKA) is developing, we aimed to determine if levels of routine point-of-care capillary blood ketones could predict future DKA." | 3.30 | Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes. ( Bakhsh, A; Bapat, P; Budhram, D; Cherney, DZI; Dhaliwal, S; Fralick, M; Ivers, NM; Lovblom, LE; Mumford, D; Perkins, BA; Scarr, D; Song, C; Tomlinson, G; Verhoeff, NJ; Weisman, A, 2023) |
| "Study 1: patients with type 1 diabetes (T1D) (n = 9) were investigated after a) insulin deprivation and lipopolysaccharide (LPS) injection and b) insulin-controlled euglycemia." | 3.01 | Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans. ( Bjerre, M; Lauritzen, ES; Møller, N; Svart, MV; Voss, T, 2021) |
| "In patients with type 1 diabetes, confirmed DKA incidence increased when sotagliflozin was added to insulin compared with insulin alone." | 2.94 | Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. ( Banks, P; Danne, T; Davies, MJ; Dhatariya, K; Jiang, W; Kushner, JA; Lapuerta, P; McGuire, DK; Peters, AL; Rodbard, HW; Sawhney, S, 2020) |
| "Nine individuals with type 1 diabetes from a previously published cohort were investigated twice at Aarhus University Hospital using a 120 min infusion of insulin (3." | 2.84 | Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes. ( Jessen, N; Kampmann, U; Møller, N; Rittig, N; Svart, MV; Voss, TS, 2017) |
| "Youth with type 1 diabetes (T1D) infrequently achieve HbA1c targets." | 2.84 | Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. ( Aschemeier, B; Biester, T; Danne, T; Fath, M; Frey, M; Kordonouri, O; Scheerer, MF, 2017) |
| "Systems that suspend basal insulin for 2 h are safe and do not lead to clinically significant ketonemia even if the blood glucose level is elevated at the time of the suspension." | 2.79 | Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. ( Carria, L; Cengiz, E; Michaud, C; Palau Collazo, M; Sherr, JL; Steffen, AT; Tamborlane, WV; Tichy, E; Weinzimer, SA; Weyman, K; Zgorski, M, 2014) |
| "We enrolled 12 patients with type 1 diabetes (men with an average age of 33." | 2.76 | Influence of physical activity on metabolic state within a 3-h interruption of continuous subcutaneous insulin infusion in patients with type 1 diabetes. ( Gruberova, J; Jankovec, Z; Komorousova, J; Krcma, M; Rusavy, Z; Tomesova, J; Zourek, M, 2011) |
| "During 3 months 45 patients with type 1 diabetes since 1-10 years old (mean 4." | 2.70 | When should determination of ketonemia be recommended? ( Ludvigsson, J; Samuelsson, U, 2002) |
| " Earlier basal NPH dosage alone does not ameliorate the nighttime hyperglycemia of short-acting insulin analog regimens." | 2.69 | Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. ( Ahmed, AB; Home, PD; Mallias, J, 1998) |
| "People with type 1 diabetes frequently encounter elevated levels of the ketone bodies acetoacetate (AA), beta-hydroxybutyrate (BHB), and acetone (ACE)." | 2.69 | Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients. ( Jain, SK; McVie, R, 1999) |
| "In diabetes, mainly type-1, ketoacidosis is the pathological response to glucose malabsorption." | 2.66 | Modulation of Cellular Biochemistry, Epigenetics and Metabolomics by Ketone Bodies. Implications of the Ketogenic Diet in the Physiology of the Organism and Pathological States. ( Balcerczyk, A; Dąbek, A; Pirola, L; Wojtala, M, 2020) |
| "Diabetic ketoacidosis is a life-threatening complication of Type 1 diabetes." | 2.49 | Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in Type 1 diabetes: a systematic review. ( Craig, ME; Klocker, AA; Phelan, H; Twigg, SM, 2013) |
| " Some patients have inadvertently dosed or overdosed while awake or during sleep, causing fatal outcome in rare cases." | 2.43 | Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents. ( Hanas, R; Ludvigsson, J, 2006) |
| "However, the degree of ketosis seen is much lower than we expected, and significantly lower than the level typically associated with diabetic ketoacidosis." | 1.91 | Type 1 diabetes and low carbohydrate diets-Defining the degree of nutritional ketosis. ( Dyson, P; Karpe, F; Matheou, M; Ozoran, H; Tan, GD, 2023) |
| "There were 23 admissions for diabetic ketoacidosis (DKA) or hyperosmolar state." | 1.51 | The Significance of an Increased Beta-Hydroxybutyrate at Presentation to the Emergency Department in Patients with Diabetes in the Absence of a Hyperglycemic Emergency. ( Chiew, AL; Depczynski, B; Lee, ATK; Varndell, W, 2019) |
| " The pediatricians reported two limitations about blood 3HB dosage compared to the urinary test: the invasiveness of capillary blood collection, and the cost of supplies for finger pricking, reagent strips and reflectance meter." | 1.51 | Clinical utility of beta-hydroxybutyrate measurement in the management of physiological ketosis at home in children under 5. ( Di Mauro, D; Dodi, I; Fainardi, V; Fanelli, U; Incerti, T; Iovane, B; Mastrorilli, C; Scarabello, C; Tchana, B; Vanelli, M; Veronese, P, 2019) |
| "Hypothermia and diabetic ketoacidosis are both potentially fatal conditions, which have historically been considered to have associated pathognomonic pathologies." | 1.48 | Basal Subnuclear Vacuolization, Armanni-Ebstein Lesions, Wischnewsky Lesions, and Elevated Vitreous Glucose and β-Hydroxybuyrate: Is It Hypothermia, Diabetic Ketoacidosis, or Both? ( Garland, J; Kesha, K; Stables, S; Triggs, Y; Tse, R; Yap, Z, 2018) |
| "When the extended family history of type 1 diabetes is considered, the proportion of sporadic diabetes cases may be reduced to <80%." | 1.39 | Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. ( Härkönen, T; Ilonen, J; Knip, M; Parkkola, A; Ryhänen, SJ, 2013) |
| "Several postmortem changes were evident." | 1.37 | Diagnosis of fulminant type 1 diabetes mellitus in an autopsy case with postmortem changes. ( Ishii, A; Kaneko, R; Mizutani, T; Yoshimoto, T, 2011) |
| "Type 1 diabetes is associated with elevated levels of blood PAI-1 and cardiovascular disease (CVD) incidence." | 1.37 | Effects of high glucose and ketosis (acetoacetate, ss-hydroxybutyrate) on PAI-1 secretion in human umbilical vascular endothelial cells. ( Jain, SK; Velusamy, T, 2011) |
| "In individuals with type 1 diabetes, hypoglycemia is a common consequence of overinsulinization." | 1.36 | Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. ( An, Z; Cherrington, AD; Farmer, B; Farmer, T; Irimia, JM; Lautz, M; Ramnanan, CJ; Rivera, N; Roach, PJ; Smith, M; Snead, W, 2010) |
| "Current criteria for the diagnosis of diabetic ketoacidosis (DKA) are limited by their nonspecificity (serum bicarbonate [HCO(3)] and pH) and qualitative nature (the presence of ketonemia/ketonuria)." | 1.35 | Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? ( Basu, A; Karon, BS; Kudva, YC; Miles, JM; Muller, LA; Schwenk, WF; Sheikh-Ali, M; Xu, J, 2008) |
| "A total of 18 patients with type 1 diabetes treated by external pump were studied during pump stop for 5 h." | 1.32 | Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. ( Benichou, M; Bohme, P; Drouin, P; Floriot, M; Fougnot, S; Franck, P; Guerci, B, 2003) |
| "Diabetic TPN rats without insulin treatment had weight loss and negative nitrogen balance during the experiment." | 1.30 | MCT/LCT emulsion ameliorate liver fat deposition in insulin-treated diabetic rats receiving total parenteral nutrition. ( Chen, WJ; Lin, MT; Yeh, SL, 1998) |
| "Compared with nondiabetic subjects, IDDM with or without CDAN exhibited reduced epinephrine (P = 0." | 1.29 | Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. ( Craft, S; Cryer, PE; Dagogo-Jack, SE, 1993) |
| "From 1981 to 1994, 112 IDDM patients were on IT." | 1.29 | Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. ( Annibale, B; Bartocci, L; Bolli, GB; Brunetti, P; Ciofetta, M; Di Vincenzo, A; Epifano, L; Fanelli, C; Lalli, C; Lepore, M; Modarelli, F; Pampanelli, S; Rambotti, AM; Sindaco, PD, 1996) |
| "Twenty-six adolescents with IDDM and 34 healthy siblings underwent measurement of their overnight GH secretory profiles (20." | 1.28 | Impact of increased growth hormone secretion on carbohydrate metabolism in adolescents with diabetes. ( Dunger, DB; Edge, JA; Holly, JM; Matthews, DR; Pal, R; Taylor, AM, 1991) |
| "In the IDDM subjects, the mean reductions in glucose concentration were 99 mg% and 84 mg% during continuous and intermittent exercise, respectively." | 1.27 | Responses to continuous and intermittent exercise in healthy and insulin-dependent diabetic children. ( Cerny, FJ; Sills, IN, 1983) |
| "On the other hand, patients with IDDM in poor metabolic control also have high circulating ketone body levels." | 1.27 | Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate. ( Angeli, P; Bressan, M; Cernigoi, A; De Donà, C; De Riva, C; Doria, A; Fioretto, P; Pauletto, N; Trevisan, R; Velussi, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (21.99) | 18.7374 |
| 1990's | 48 (34.04) | 18.2507 |
| 2000's | 28 (19.86) | 29.6817 |
| 2010's | 26 (18.44) | 24.3611 |
| 2020's | 8 (5.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akturk, HK | 1 |
| Snell-Bergeon, J | 1 |
| Pyle, L | 1 |
| Fivekiller, E | 1 |
| Garg, S | 1 |
| Cobry, E | 1 |
| Tremblay, ES | 1 |
| Millington, K | 1 |
| Wu, Y | 1 |
| Wypij, D | 1 |
| Yang, Y | 1 |
| Agus, MSD | 1 |
| Wolfsdorf, J | 1 |
| Ozoran, H | 1 |
| Matheou, M | 1 |
| Dyson, P | 1 |
| Karpe, F | 1 |
| Tan, GD | 1 |
| Song, C | 1 |
| Dhaliwal, S | 1 |
| Bapat, P | 1 |
| Scarr, D | 1 |
| Bakhsh, A | 1 |
| Budhram, D | 1 |
| Verhoeff, NJ | 1 |
| Weisman, A | 1 |
| Fralick, M | 1 |
| Ivers, NM | 1 |
| Cherney, DZI | 1 |
| Tomlinson, G | 1 |
| Lovblom, LE | 1 |
| Mumford, D | 1 |
| Perkins, BA | 1 |
| Depczynski, B | 1 |
| Lee, ATK | 1 |
| Varndell, W | 1 |
| Chiew, AL | 1 |
| Dąbek, A | 1 |
| Wojtala, M | 1 |
| Pirola, L | 1 |
| Balcerczyk, A | 1 |
| Peters, AL | 1 |
| McGuire, DK | 1 |
| Danne, T | 2 |
| Kushner, JA | 1 |
| Rodbard, HW | 1 |
| Dhatariya, K | 1 |
| Sawhney, S | 1 |
| Banks, P | 1 |
| Jiang, W | 1 |
| Davies, MJ | 1 |
| Lapuerta, P | 1 |
| Hancock, G | 1 |
| Sharma, S | 1 |
| Galpin, M | 1 |
| Lunn, D | 1 |
| Megson, C | 1 |
| Peverall, R | 1 |
| Richmond, G | 1 |
| Ritchie, GAD | 1 |
| Owen, KR | 1 |
| Lauritzen, ES | 1 |
| Svart, MV | 2 |
| Voss, T | 1 |
| Møller, N | 5 |
| Bjerre, M | 1 |
| Rittig, N | 1 |
| Kampmann, U | 1 |
| Voss, TS | 1 |
| Jessen, N | 1 |
| Biester, T | 1 |
| Aschemeier, B | 1 |
| Fath, M | 1 |
| Frey, M | 1 |
| Scheerer, MF | 1 |
| Kordonouri, O | 1 |
| Tse, R | 1 |
| Garland, J | 1 |
| Kesha, K | 1 |
| Triggs, Y | 1 |
| Yap, Z | 1 |
| Stables, S | 1 |
| Iovane, B | 2 |
| Cangelosi, AM | 1 |
| Bonaccini, I | 1 |
| Di Mauro, D | 2 |
| Scarabello, C | 2 |
| Panigari, A | 1 |
| Tiri, A | 1 |
| Mastrorilli, C | 2 |
| Fainardi, V | 2 |
| Dodi, I | 2 |
| Vanelli, M | 3 |
| Siebel, S | 1 |
| Galderisi, A | 1 |
| Patel, NS | 1 |
| Carria, LR | 1 |
| Tamborlane, WV | 3 |
| Sherr, JL | 2 |
| Veronese, P | 1 |
| Fanelli, U | 1 |
| Incerti, T | 1 |
| Tchana, B | 1 |
| Palau Collazo, M | 1 |
| Cengiz, E | 1 |
| Michaud, C | 1 |
| Carria, L | 1 |
| Steffen, AT | 1 |
| Weyman, K | 1 |
| Zgorski, M | 1 |
| Tichy, E | 1 |
| Weinzimer, SA | 1 |
| Sadek, KM | 1 |
| Shaheen, H | 1 |
| Samudrala, D | 1 |
| Lammers, G | 1 |
| Mandon, J | 1 |
| Blanchet, L | 1 |
| Schreuder, TH | 1 |
| Hopman, MT | 1 |
| Harren, FJ | 1 |
| Tappy, L | 1 |
| Cristescu, SM | 1 |
| Palmiere, C | 1 |
| Neumann, UH | 1 |
| Denroche, HC | 1 |
| Mojibian, M | 1 |
| Covey, SD | 1 |
| Kieffer, TJ | 1 |
| Henry, RR | 1 |
| Dandona, P | 1 |
| Pettus, J | 1 |
| Mudaliar, S | 1 |
| Xu, J | 2 |
| Hansen, L | 1 |
| Lee, P | 1 |
| Greenfield, JR | 1 |
| Campbell, LV | 1 |
| Page, KA | 1 |
| Williamson, A | 1 |
| Yu, N | 1 |
| McNay, EC | 1 |
| Dzuira, J | 1 |
| McCrimmon, RJ | 1 |
| Sherwin, RS | 3 |
| Warren, R | 1 |
| Velusamy, T | 1 |
| Jain, SK | 4 |
| Rivera, N | 1 |
| Ramnanan, CJ | 1 |
| An, Z | 1 |
| Farmer, T | 1 |
| Smith, M | 1 |
| Farmer, B | 1 |
| Irimia, JM | 1 |
| Snead, W | 1 |
| Lautz, M | 1 |
| Roach, PJ | 1 |
| Cherrington, AD | 2 |
| Bracken, RM | 1 |
| West, DJ | 1 |
| Stephens, JW | 1 |
| Kilduff, LP | 1 |
| Luzio, S | 1 |
| Bain, SC | 1 |
| Mizutani, T | 1 |
| Yoshimoto, T | 1 |
| Kaneko, R | 1 |
| Ishii, A | 1 |
| Jankovec, Z | 1 |
| Krcma, M | 1 |
| Gruberova, J | 1 |
| Komorousova, J | 1 |
| Tomesova, J | 1 |
| Zourek, M | 1 |
| Rusavy, Z | 1 |
| Weingart, C | 1 |
| Lotz, F | 1 |
| Kohn, B | 1 |
| Dutta, T | 1 |
| Chai, HS | 1 |
| Ward, LE | 1 |
| Ghosh, A | 1 |
| Persson, XM | 1 |
| Ford, GC | 1 |
| Kudva, YC | 2 |
| Sun, Z | 1 |
| Asmann, YW | 1 |
| Kocher, JP | 1 |
| Nair, KS | 1 |
| Gambhir, D | 1 |
| Ananth, S | 1 |
| Veeranan-Karmegam, R | 1 |
| Elangovan, S | 1 |
| Hester, S | 1 |
| Jennings, E | 1 |
| Offermanns, S | 1 |
| Nussbaum, JJ | 1 |
| Smith, SB | 1 |
| Thangaraju, M | 1 |
| Ganapathy, V | 1 |
| Martin, PM | 1 |
| Zeugswetter, FK | 1 |
| Rebuzzi, L | 1 |
| Parkkola, A | 1 |
| Härkönen, T | 1 |
| Ryhänen, SJ | 1 |
| Ilonen, J | 1 |
| Knip, M | 1 |
| Klocker, AA | 1 |
| Phelan, H | 1 |
| Twigg, SM | 1 |
| Craig, ME | 1 |
| Hsu, TT | 1 |
| Leiske, DL | 1 |
| Rosenfeld, L | 1 |
| Sonner, JM | 1 |
| Fuller, GG | 1 |
| Yamanouchi, K | 1 |
| Abe, R | 1 |
| Takeda, A | 1 |
| Atsumi, Y | 1 |
| Shichiri, M | 1 |
| Sato, Y | 1 |
| Harano, Y | 1 |
| Samuelsson, U | 1 |
| Ludvigsson, J | 2 |
| Jacob, RJ | 1 |
| Fan, X | 1 |
| Evans, ML | 1 |
| Dziura, J | 1 |
| Chiari, G | 1 |
| Capuano, C | 1 |
| Guerci, B | 3 |
| Benichou, M | 1 |
| Floriot, M | 1 |
| Bohme, P | 1 |
| Fougnot, S | 1 |
| Franck, P | 1 |
| Drouin, P | 2 |
| Linke, A | 1 |
| Zhao, G | 1 |
| Recchia, FA | 1 |
| Williams, J | 1 |
| Xu, X | 1 |
| Hintze, TH | 1 |
| Matta, MP | 1 |
| Melki, V | 2 |
| Bessière-Lacombe, S | 1 |
| Hanaire-Broutin, H | 2 |
| Tubiana-Rufi, N | 1 |
| Bauduceau, B | 1 |
| Bresson, R | 1 |
| Cuperlier, A | 1 |
| Delcroix, C | 1 |
| Durain, D | 1 |
| Fermon, C | 1 |
| Le Floch, JP | 1 |
| Le Devehat, C | 1 |
| Monnier, L | 1 |
| Mosnier-Pudar, H | 1 |
| Taboulet, P | 1 |
| Orsini-Federici, M | 1 |
| Akwi, JA | 1 |
| Canonico, V | 2 |
| Celleno, R | 1 |
| Ferolla, P | 1 |
| Pippi, R | 1 |
| Tassi, C | 1 |
| Timi, A | 1 |
| Benedetti, MM | 1 |
| Laffel, LM | 1 |
| Wentzell, K | 1 |
| Loughlin, C | 1 |
| Tovar, A | 1 |
| Moltz, K | 1 |
| Brink, S | 1 |
| Hanas, R | 1 |
| Fabietti, PG | 1 |
| Orsini Federici, M | 1 |
| Sarti, E | 1 |
| Massi Benedetti, M | 1 |
| Saukkonen, T | 1 |
| Shojaee-Moradie, F | 1 |
| Williams, RM | 1 |
| Amin, R | 1 |
| Yuen, KC | 1 |
| Watts, A | 1 |
| Acerini, CL | 2 |
| Umpleby, AM | 2 |
| Dunger, DB | 5 |
| Prisco, F | 1 |
| Picardi, A | 1 |
| Iafusco, D | 1 |
| Lorini, R | 1 |
| Minicucci, L | 1 |
| Martinucci, ME | 1 |
| Toni, S | 1 |
| Cerutti, F | 1 |
| Rabbone, I | 1 |
| Buzzetti, R | 1 |
| Crino, A | 1 |
| Pozzilli, P | 1 |
| Pelletier, A | 1 |
| Coderre, L | 1 |
| López Siguero, JP | 1 |
| Moreno Molina, JA | 1 |
| Borrás Pérez, MV | 1 |
| Pinzón Martín, JL | 1 |
| Brea Molina, JI | 1 |
| del Pino de la Fuente, A | 1 |
| Parramón Pons, M | 1 |
| Geddes, J | 1 |
| Deans, KA | 1 |
| Cormack, A | 1 |
| Motherwell, D | 1 |
| Paterson, K | 1 |
| O'Reilly, DS | 1 |
| Fisher, BM | 1 |
| Sheikh-Ali, M | 1 |
| Karon, BS | 1 |
| Basu, A | 1 |
| Muller, LA | 1 |
| Schwenk, WF | 1 |
| Miles, JM | 2 |
| Rosak, C | 1 |
| Jung, R | 1 |
| Hofmann, U | 1 |
| Schmitz, O | 6 |
| Rømer, FK | 1 |
| Alberti, KG | 12 |
| Hreidarsson, AB | 1 |
| Orskov, H | 3 |
| Sills, IN | 1 |
| Cerny, FJ | 1 |
| Nankervis, A | 1 |
| Proietto, J | 1 |
| Aitken, P | 1 |
| Alford, F | 1 |
| Capaldo, B | 1 |
| Home, PD | 3 |
| Massi-Benedetti, M | 1 |
| Worth, R | 1 |
| Cook, DB | 1 |
| Heaton, A | 1 |
| Hall, SE | 1 |
| Wastney, ME | 1 |
| Bolton, TM | 1 |
| Braaten, JT | 1 |
| Berman, M | 1 |
| Nicholson, JK | 1 |
| O'Flynn, MP | 1 |
| Sadler, PJ | 1 |
| Macleod, AF | 1 |
| Juul, SM | 1 |
| Sönksen, PH | 1 |
| Hertz, RH | 1 |
| King, KC | 1 |
| Kalhan, SC | 1 |
| Dagogo-Jack, S | 2 |
| Rattarasarn, C | 2 |
| Cryer, PE | 8 |
| Nisell, H | 1 |
| Persson, B | 3 |
| Hanson, U | 1 |
| Lunell, NO | 1 |
| Nylund, L | 1 |
| Sarby, B | 1 |
| Thronström, S | 1 |
| Zachwieja, JJ | 1 |
| Davis, SN | 1 |
| Goldstein, RE | 1 |
| Price, L | 1 |
| Robert, JJ | 1 |
| Chauvet, D | 1 |
| Darmaun, D | 1 |
| Leblanc, H | 1 |
| Fanelli, C | 2 |
| Di Vincenzo, A | 3 |
| Modarelli, F | 3 |
| Lepore, M | 3 |
| Ciofetta, M | 4 |
| Epifano, L | 3 |
| Pampanelli, S | 5 |
| Brunetti, P | 5 |
| Bolli, GB | 4 |
| Edge, JA | 2 |
| Harris, DA | 2 |
| Phillips, PE | 2 |
| Pal, BR | 2 |
| Matthews, DR | 4 |
| Wiethop, BV | 1 |
| Serlenga, E | 1 |
| Garofalo, AR | 1 |
| De Pergola, G | 1 |
| Ventura, MT | 1 |
| Tortorella, C | 1 |
| Antonaci, S | 1 |
| Dagogo-Jack, SE | 1 |
| Craft, S | 1 |
| Teraki, Y | 1 |
| Teraki, E | 1 |
| Kawashima, M | 1 |
| Nagashima, M | 1 |
| Shiohara, T | 1 |
| Avogaro, A | 5 |
| Crepaldi, C | 1 |
| Piarulli, F | 1 |
| Milan, D | 1 |
| Valerio, A | 1 |
| Pavan, P | 1 |
| Sacerdoti, D | 1 |
| Calabrò, A | 1 |
| Macdonald, I | 1 |
| Crepaldi, G | 1 |
| Scognamiglio, R | 1 |
| Tiengo, A | 2 |
| Torlone, E | 2 |
| Ialli, C | 1 |
| Del Sindaco, P | 3 |
| Bartocci, L | 2 |
| Lalli, C | 2 |
| Sindaco, PD | 1 |
| Rambotti, AM | 2 |
| Annibale, B | 1 |
| Kassi, G | 1 |
| Perriello, G | 1 |
| Bolli, G | 1 |
| Dejgaard, A | 1 |
| Andersen, P | 1 |
| Hvidberg, A | 1 |
| Hilsted, J | 2 |
| Bottini, P | 1 |
| Boschetti, E | 1 |
| Scionti, L | 1 |
| Divertie, GD | 1 |
| Jensen, MD | 1 |
| Jacobs, MA | 1 |
| Keulen, ET | 1 |
| Kanc, K | 1 |
| Casteleijn, S | 1 |
| Scheffer, P | 1 |
| Devillé, W | 1 |
| Heine, RJ | 1 |
| Wiggam, MI | 1 |
| O'Kane, MJ | 1 |
| Harper, R | 1 |
| Atkinson, AB | 1 |
| Hadden, DR | 1 |
| Trimble, ER | 1 |
| Bell, PM | 1 |
| Ahmed, AB | 1 |
| Mallias, J | 1 |
| Pounder, DJ | 1 |
| Stevenson, RJ | 1 |
| Taylor, KK | 1 |
| Jovanovic, L | 1 |
| Metzger, BE | 1 |
| Knopp, RH | 1 |
| conley, MR | 1 |
| Park, E | 1 |
| Lee, YJ | 1 |
| Simpson, JL | 1 |
| Holmes, L | 1 |
| Aarons, JH | 1 |
| Mills, JL | 1 |
| Matyka, KA | 1 |
| Watts, AP | 1 |
| Russell-Jones, DL | 1 |
| Rudberg, S | 1 |
| Yeh, SL | 1 |
| Lin, MT | 1 |
| Chen, WJ | 1 |
| McVie, R | 3 |
| Jackson, R | 1 |
| Levine, SN | 1 |
| Lim, G | 2 |
| Meyer, L | 1 |
| Sallé, A | 1 |
| Charrié, A | 1 |
| Dousset, B | 1 |
| Ziegler, O | 1 |
| Koster, JC | 1 |
| Marshall, BA | 1 |
| Ensor, N | 1 |
| Corbett, JA | 1 |
| Nichols, CG | 1 |
| Fisher, SJ | 1 |
| Shi, ZQ | 1 |
| Lickley, HL | 1 |
| Efendic, S | 1 |
| Vranic, M | 1 |
| Giacca, A | 1 |
| Wallace, TM | 1 |
| Meston, NM | 1 |
| Gardner, SG | 1 |
| Bischof, MG | 1 |
| Bernroider, E | 1 |
| Ludwig, C | 1 |
| Kurzemann, S | 1 |
| Kletter, K | 1 |
| Waldhäusl, W | 1 |
| Roden, M | 1 |
| Blomqvist, G | 1 |
| Alvarsson, M | 1 |
| Grill, V | 1 |
| Von Heijne, G | 1 |
| Ingvar, M | 1 |
| Thorell, JO | 1 |
| Stone-Elander, S | 1 |
| Widén, L | 1 |
| Ekberg, K | 1 |
| Kannan, K | 1 |
| Bocchini, JA | 1 |
| Luzi, L | 2 |
| Battezzati, A | 1 |
| Perseghin, G | 1 |
| Bianchi, E | 1 |
| Vergani, S | 1 |
| Secchi, A | 2 |
| La Rocca, E | 1 |
| Staudacher, C | 1 |
| Spotti, D | 1 |
| Ferrari, G | 1 |
| McGarry, JD | 1 |
| Boyle, PJ | 1 |
| Smith, L | 1 |
| Shah, SD | 3 |
| Santiago, JV | 1 |
| Yajnik, CS | 1 |
| Shelgikar, KM | 1 |
| Naik, SS | 1 |
| Kanitkar, SV | 1 |
| Hockaday, TD | 1 |
| Pal, R | 1 |
| Taylor, AM | 1 |
| Holly, JM | 1 |
| Watanabe, T | 1 |
| Sugiyama, H | 1 |
| Uchimura, I | 1 |
| Maezawa, H | 1 |
| Orskov, L | 2 |
| Mengel, A | 1 |
| Pedersen, O | 1 |
| Rasmussen, O | 1 |
| Seefeldt, T | 1 |
| Larsen, S | 1 |
| Philipsen, EK | 1 |
| Tronier, B | 1 |
| Damkjaer Nielsen, M | 1 |
| Worning, H | 1 |
| Weinstein, I | 1 |
| Patel, TB | 1 |
| Heimberg, M | 1 |
| Hagström-Toft, E | 1 |
| Arner, P | 2 |
| Näslund, B | 1 |
| Ungerstedt, U | 1 |
| Bolinder, J | 2 |
| Ubukata, E | 1 |
| Scott, AR | 1 |
| Macdonald, IA | 1 |
| Bowman, CA | 1 |
| Jeffcoate, WJ | 1 |
| Wahrenberg, H | 1 |
| Adamsson, U | 1 |
| Lins, PE | 1 |
| Juhlin-Dannfelt, A | 1 |
| Ostman, J | 2 |
| Hirsch, IB | 1 |
| Smith, LJ | 1 |
| Havlin, CE | 1 |
| Clutter, WE | 2 |
| Jørgensen, JO | 2 |
| Møller, J | 2 |
| Bak, JF | 1 |
| Pørksen, N | 2 |
| Nosadini, R | 3 |
| Doria, A | 2 |
| Tremolada, C | 1 |
| Baccaglini, U | 1 |
| Ambrosio, F | 1 |
| Merkel, C | 1 |
| Nosadini, A | 1 |
| Trevisan, R | 4 |
| Fioretto, P | 2 |
| Bennet, WM | 1 |
| Connacher, AA | 1 |
| Smith, K | 1 |
| Jung, RT | 1 |
| Rennie, MJ | 1 |
| Gunnarsson, R | 1 |
| Brattström, C | 1 |
| Tydén, G | 1 |
| Wahren, J | 1 |
| Groth, CG | 1 |
| Scheen, AJ | 1 |
| Gillet, J | 1 |
| Rosenthaler, J | 1 |
| Guiot, J | 1 |
| Henrivaux, P | 1 |
| Jandrain, B | 1 |
| Lefèbvre, PJ | 1 |
| Haakens, K | 1 |
| Hanssen, KF | 1 |
| Dahl-Jørgensen, K | 1 |
| Vaaler, S | 1 |
| Torjesen, P | 1 |
| Try, K | 1 |
| Aarsen, RS | 1 |
| Bruining, GJ | 1 |
| Grose, WF | 1 |
| van Strik, R | 1 |
| Lamberts, SW | 1 |
| Harris, AG | 1 |
| Hagenfeldt, L | 1 |
| Dahlquist, G | 1 |
| Gray, RS | 1 |
| Cowan, P | 1 |
| Duncan, LJ | 1 |
| Clarke, BF | 1 |
| Mitchell, TH | 1 |
| Abraham, G | 1 |
| Schiffrin, A | 1 |
| Leiter, LA | 1 |
| Marliss, EB | 1 |
| Wilson, RM | 1 |
| Reeves, WG | 1 |
| Barrett, EJ | 1 |
| Groop, LC | 1 |
| Ferrannini, E | 1 |
| DeFronzo, RA | 1 |
| Tuttle, KR | 1 |
| Marker, JC | 1 |
| Dalsky, GP | 1 |
| Schwartz, NS | 1 |
| Holloszy, JO | 1 |
| Velussi, M | 1 |
| Cernigoi, A | 1 |
| De Riva, C | 1 |
| Bressan, M | 1 |
| Pauletto, N | 1 |
| Angeli, P | 1 |
| De Donà, C | 1 |
| Husband, DJ | 1 |
| Pernet, A | 1 |
| Gill, GV | 1 |
| Hanning, I | 4 |
| Francis, AJ | 2 |
| Press, M | 1 |
| Hermansen, K | 1 |
| Møller, A | 1 |
| Christensen, CK | 1 |
| Christiansen, JS | 1 |
| Mogensen, CE | 1 |
| Zuniga-Guajardo, S | 1 |
| Zinman, B | 1 |
| Jimenez, JT | 1 |
| Walford, S | 1 |
| Krarup, T | 1 |
| Madsbad, S | 1 |
| Regeur, L | 1 |
| Faber, OK | 1 |
| Kurtz, A | 1 |
| Féry, F | 1 |
| Balasse, EO | 1 |
| Duner, E | 1 |
| Marescotti, C | 1 |
| Iori, E | 1 |
| Cobelli, C | 2 |
| Toffolo, G | 2 |
| Pozza, G | 1 |
| Bosi, E | 1 |
| Piatti, PM | 1 |
| Touraine, JL | 1 |
| Gelet, A | 1 |
| Pontiroli, AE | 1 |
| Dubernard, JM | 1 |
| Traeger, J | 1 |
| Saccà, L | 1 |
| Vigorito, C | 1 |
| de Kreutzenberg, S | 1 |
| Tessari, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control[NCT02421510] | Phase 3 | 782 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control[NCT02384941] | Phase 3 | 793 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency[NCT05541484] | Phase 4 | 20 participants (Anticipated) | Interventional | 2022-10-14 | Recruiting | ||
| Metabolic Signalling in Muscle- and Adipose Tissue Following Insulin Withdrawal and Growth Hormone Injection in Type I Diabetes Mellitus, a Clinical Experimental Study.[NCT02077348] | 9 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| The Role of ATGL and G0/G1 Switch Gene Complex in Lipopolysaccaride (LPS) Induced Ketosis - a Controlled, Randomised, Clinical Experimental Study[NCT02157155] | 9 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study[NCT02357550] | 9 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Targeted Proteomic Analysis in the Plasma of Children With Diabetes Type 1 and Its Association With Peripheral Diabetic Neuropathy[NCT04257877] | 50 participants (Anticipated) | Observational | 2018-11-20 | Recruiting | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome[NCT02122666] | 100 participants (Anticipated) | Observational | 2014-03-31 | Active, not recruiting | |||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DDS2 is a 2-item diabetes distress screening instrument where participants rated the degree to which the following items caused distress: (1) feeling overwhelmed by the demands of living with diabetes, and (2) feeling that I am often failing with my diabetes regimen using a 6-point scale: where 1=no distress to 6=severe distress for a total possible score of 2 to 12. LS means were obtained from MMRM model including all available post baseline values. A negative change from baseline indicates improvement. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.0 |
| Sotagliflozin 200 mg | -0.3 |
| Sotagliflozin 400 mg | -0.4 |
Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. Least square (LS) means were obtained from a mixed-effects model for repeated measures (MMRM) that included fixed, categorical effects of treatment, randomization strata of insulin delivery method (MDI, CSII), randomization strata of Week -2 A1C (<= 8.5%, >8.5%), time (study week), a treatment-by-time interaction, and baseline A1C-by-time interaction as a covariate. A negative change from baseline (a reduction of A1C value at Week 24) indicates an improvement. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Percentage of A1C (Least Squares Mean) |
|---|---|
| Placebo | -0.02 |
| Sotagliflozin 200 mg | -0.39 |
| Sotagliflozin 400 mg | -0.37 |
Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model. A negative change from baseline indicates a loss in body weight from baseline to Week 24. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Kilograms (kg) (Least Squares Mean) |
|---|---|
| Placebo | 0.11 |
| Sotagliflozin 200 mg | -1.88 |
| Sotagliflozin 400 mg | -2.47 |
The DTSQ instrument contains 8 items assessing overall treatment satisfaction, treatment convenience and flexibility, satisfaction with understanding of diabetes, willingness to continue present treatment and to recommend it to others, and frequency of unacceptably high and unacceptably low blood glucose levels. 6 items (1, 4, 5, 6, 7 and 8) (excluding perceived hyperglycemia and hypoglycemia items) were scored using a 7- point scale where 0=very dissatisfied to 6= very satisfied for a total possible score of 0 (very dissatisfied) to 36 (very satisfied), where higher scores indicate higher satisfaction from treatment. Two items (Q2 and 3), which were not included, measured perceived hyperglycemia and hypoglycemia, respectively. The baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model including all available post baseline values. A positive change from baseline indicates improvement. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.1 |
| Sotagliflozin 200 mg | 1.9 |
| Sotagliflozin 400 mg | 1.6 |
The Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model including all available post baseline values. A negative change from baseline indicates a lower glucose level at Week 24 compared to baseline and a positive change from baseline indicates an increase in glucose level at Week 24 compared to baseline. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Milligram per deciliter (mg/dL) (Least Squares Mean) |
|---|---|
| Placebo | 8.8 |
| Sotagliflozin 200 mg | -12.8 |
| Sotagliflozin 400 mg | -16.9 |
The mean bolus insulin dose in international units/day (IU/day) for Week 24 was the average over the 3 to 5 days prior to the Week 24 visit. The Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model including all available post baseline values. A negative change from baseline indicated a reduction in the amount of bolus insulin used and a positive change from baseline indicated an increase in the amount of bolus insulin used between baseline and Week 24. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | IU/day (Least Squares Mean) |
|---|---|
| Placebo | -1.19 |
| Sotagliflozin 200 mg | -4.38 |
| Sotagliflozin 400 mg | -4.78 |
Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model. A negative percent change from baseline indicates a loss in body weight from baseline to Week 24. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.10 |
| Sotagliflozin 200 mg | -2.38 |
| Sotagliflozin 400 mg | -2.99 |
The composite endpoint included blood samples for the assessment of Hemoglobin A1C to determine the participants with a value <7.0% and a central blinded adjudication process to determine whether participants experienced either DKA or severe hypoglycemia. Only positively adjudicated severe hypoglycemia and diabetic ketoacidosis were included in the analysis. (NCT02421510)
Timeframe: Baseline to Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 15.1 |
| Sotagliflozin 200 mg | 31.4 |
| Sotagliflozin 400 mg | 32.3 |
Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model. A negative change from Baseline indicates a loss in body weight from Baseline to Week 24. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | kilograms (kg) (Least Squares Mean) |
|---|---|
| Placebo | 0.78 |
| Sotagliflozin 200 mg | -1.57 |
| Sotagliflozin 400 mg | -2.67 |
Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. Least square (LS) means were obtained from a mixed-effects model for repeated measures (MMRM) that included fixed, categorical effects of treatment, randomization strata of insulin delivery method (MDI, CSII), randomization strata of Week -2 A1C (<= 8.5%, >8.5%), time (study week), a treatment-by-time interaction, and baseline A1C-by-time interaction as a covariate. A negative change from Baseline (a lower A1C value at Week 24) indicates an improvement. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | percentage of A1C (Least Squares Mean) |
|---|---|
| Placebo | -0.07 |
| Sotagliflozin 200 mg | -0.43 |
| Sotagliflozin 400 mg | -0.48 |
The DDS2 is a 2-item diabetes distress screening instrument where respondents rated, on a 6-point scale, the degree to which the following items caused distress: (1) feeling overwhelmed by the demands of living with diabetes, and (2) feeling that I am often failing with my diabetes regimen using a 6-point scale: where 1=no distress to 6=severe distress for a total possible score of 2 (not a problem) to 12 (very serious problem), with higher score corresponding to higher distress. LS means were obtained from MMRM model including all available post baseline values. A negative change from baseline indicates improvement. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Sotagliflozin 200 mg | -0.4 |
| Sotagliflozin 400 mg | -0.5 |
DTSQs is a diabetes-specific measure used to evaluate overall treatment satisfaction and perception of hyperglycemia and hypoglycemia events. It consists of 8 items and the response categories for all items were on a 7-point likert scale.The DTSQs response options ranged from 0 (very dissatisfied) to 6 (very satisfied). Responses to item 1, 4, 5, 6, 7 and 8 were summarized to determine the total treatment satisfaction score which ranged from 0 (very dissatisfied) to 36 (very satisfied), with a higher score corresponding to higher satisfaction . LS means were obtained from MMRM model including all available post baseline values. A positive change from baseline indicates improvement. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Sotagliflozin 200 mg | 2.1 |
| Sotagliflozin 400 mg | 2.1 |
The Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model including all available post baseline values. A negative change from baseline indicates a lower glucose at Week 24 compared to baseline. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | millimole per liter (mmol/L) (Least Squares Mean) |
|---|---|
| Placebo | 0.21 |
| Sotagliflozin 200 mg | -0.34 |
| Sotagliflozin 400 mg | -0.78 |
The mean bolus insulin dose in international units per day (IU/day) for Week 24 was the average over the 3 to 5 days prior to the Week 24 visit. The Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model including all available post Baseline values. A negative change from Baseline indicated a reduction in the amount of bolus insulin used between Baseline and Week 24. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | IU/day (Least Squares Mean) |
|---|---|
| Placebo | -0.84 |
| Sotagliflozin 200 mg | -2.33 |
| Sotagliflozin 400 mg | -4.13 |
Baseline value was defined as the last value collected prior to the first dose of double-blind study medication. LS means were obtained from MMRM model. A negative percent change from baseline indicates a loss in body weight from baseline to Week 24. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.92 |
| Sotagliflozin 200 mg | -1.87 |
| Sotagliflozin 400 mg | -3.10 |
Blood samples were collected for the assessment of Hemoglobin A1C to determine the participants with A1C value <7.0%. A central blinded adjudication process determined whether participants experienced either DKA or Severe Hypoglycemia. Only positively adjudicated severe hypoglycemia and diabetic ketoacidosis were included in the analysis. (NCT02384941)
Timeframe: Baseline to Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 21.6 |
| Sotagliflozin 200 mg | 33.5 |
| Sotagliflozin 400 mg | 43.5 |
6 reviews available for 3-hydroxybutyric acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Modulation of Cellular Biochemistry, Epigenetics and Metabolomics by Ketone Bodies. Implications of the Ketogenic Diet in the Physiology of the Organism and Pathological States.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Diabetes Mellitus, Type 1; Diet, Ketogenic; Epigenesi | 2020 |
Postmortem diagnosis of diabetes mellitus and its complications.
Topics: 3-Hydroxybutyric Acid; Autopsy; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Forensic Pathology | 2015 |
Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in Type 1 diabetes: a systematic review.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Critical Care; Crown-Rump Length; Diabetes Mellitus, Type 1; D | 2013 |
[Blood level of ketone bodies and its clinical significance].
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2002 |
Advantages to using capillary blood beta-hydroxybutyrate determination for the detection and treatment of diabetic ketosis.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Biomarkers; Capillaries; Child; Diabetes Mellitus, Type 1; | 2005 |
Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents.
Topics: 3-Hydroxybutyric Acid; Adolescent; Blood Glucose; Child; Clinical Trials as Topic; Diabetes Mellitus | 2006 |
27 trials available for 3-hydroxybutyric acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes.
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Humans; Ketones; Ketosis; P | 2023 |
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; | 2020 |
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; | 2020 |
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; | 2020 |
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; | 2020 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Topics: 3-Hydroxybutyric Acid; Adult; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Fibroblast Grow | 2021 |
Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Biopsy; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; | 2017 |
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Benzhydryl Compounds; Child; Cross-Over Studies; Diabetes | 2017 |
Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoaci | 2014 |
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Topics: 3-Hydroxybutyric Acid; Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Di | 2017 |
Impact of pre-exercise rapid-acting insulin reductions on ketogenesis following running in Type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 1; Energy Meta | 2011 |
Influence of physical activity on metabolic state within a 3-h interruption of continuous subcutaneous insulin infusion in patients with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Acid-Base Equilibrium; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mel | 2011 |
When should determination of ketonemia be recommended?
Topics: 3-Hydroxybutyric Acid; Adolescent; Blood Glucose; C-Peptide; Child; Child, Preschool; Circadian Rhyt | 2002 |
Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated patients with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glycated | 2006 |
Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Blood Glucose; Blood Glucose Self-Monitoring; Child; Child | 2006 |
Model based study on monitoring ketone bodies to improve safety in intensive insulin therapy.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Capillaries; Diabetes Mellitus, Type 1; Humans; Insulin Infusi | 2006 |
Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type | 2006 |
Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Eating; Fatty Acids, Noneste | 2008 |
Alanine and terbutaline in treatment of hypoglycemia in IDDM.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Alanine; Blood Glucose; C-Peptide; Diabetes Mellitus, T | 1993 |
The hemodynamic abnormalities in short-term insulin deficiency: the role of prostaglandin inhibition.
Topics: 3-Hydroxybutyric Acid; 6-Ketoprostaglandin F1 alpha; Acetoacetates; Adult; Blood Glucose; Diabetes M | 1996 |
Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Blood Glucose; Child; Cross-Over Studies; Diabetes Mellitu | 1997 |
Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study.
Topics: 3-Hydroxybutyric Acid; Adult; Bicarbonates; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Keto | 1997 |
Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus | 1998 |
Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; D | 1998 |
Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Fatty Ac | 1999 |
Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Child; Diabetes Mellitus, Type 1; Erythrocytes; Gluta | 1999 |
Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients.
Topics: 3-Hydroxybutyric Acid; Acute Disease; Adult; Brain; Carbon Radioisotopes; Diabetes Mellitus, Type 1; | 2002 |
Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers.
Topics: 3-Hydroxybutyric Acid; Adolescent; Blood Glucose; Circadian Rhythm; Clinical Trials as Topic; Diabet | 1987 |
Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
Topics: 3-Hydroxybutyric Acid; Adult; Animals; Blood Glucose; Circadian Rhythm; Clinical Trials as Topic; Di | 1986 |
Diurnal plasma profiles of metabolite and hormone concentration in insulin-dependent diabetic patients during conventional insulin treatment and continuous subcutaneous insulin infusion. A controlled study.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Female; Gl | 1987 |
108 other studies available for 3-hydroxybutyric acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Breath Tests; Child; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; | 2021 |
Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis.
Topics: 3-Hydroxybutyric Acid; Child; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Humans; Insulin; ROC | 2022 |
Type 1 diabetes and low carbohydrate diets-Defining the degree of nutritional ketosis.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Diet, Carboh | 2023 |
The Significance of an Increased Beta-Hydroxybutyrate at Presentation to the Emergency Department in Patients with Diabetes in the Absence of a Hyperglycemic Emergency.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Child; Child, Pres | 2019 |
The correlation between breath acetone and blood betahydroxybutyrate in individuals with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Acetone; Breath Tests; Capillaries; Diabetes Mellitus, Type 1; Diabetic Ketoa | 2020 |
Basal Subnuclear Vacuolization, Armanni-Ebstein Lesions, Wischnewsky Lesions, and Elevated Vitreous Glucose and β-Hydroxybuyrate: Is It Hypothermia, Diabetic Ketoacidosis, or Both?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Epithelial Cells; Fatal Out | 2018 |
Diabetic ketoacidosis at the onset of Type 1 diabetes in young children Is it time to launch a tailored campaign for DKA prevention in children <5 years?
Topics: 3-Hydroxybutyric Acid; Adolescent; Child; Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Keto | 2018 |
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Keto | 2019 |
Clinical utility of beta-hydroxybutyrate measurement in the management of physiological ketosis at home in children under 5.
Topics: 3-Hydroxybutyric Acid; Capillaries; Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidos | 2019 |
Biochemical efficacy of vitamin D in ameliorating endocrine and metabolic disorders in diabetic rats.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2014 |
Breath acetone to monitor life style interventions in field conditions: an exploratory study.
Topics: 3-Hydroxybutyric Acid; Acetone; Adult; Aged; Breath Tests; Case-Control Studies; Diabetes Mellitus, | 2014 |
Insulin Knockout Mice Have Extended Survival but Volatile Blood Glucose Levels on Leptin Therapy.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Cholesterol; Corticosterone; Diabetes Mellitus, Exper | 2016 |
"Mind the gap" when managing ketoacidosis in type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Designer Drugs; Diabetes Mellitus, Type 1; Diabetic Ket | 2008 |
Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia.
Topics: 3-Hydroxybutyric Acid; Acute Disease; Cognition; Cognition Disorders; Diabetes Mellitus, Type 1; Fat | 2009 |
Alcoholic lunch did not cause clinically relevant ketosis.
Topics: 3-Hydroxybutyric Acid; Alcohol Drinking; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Humans | 2010 |
Effects of high glucose and ketosis (acetoacetate, ss-hydroxybutyrate) on PAI-1 secretion in human umbilical vascular endothelial cells.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Cells, Cultured; Diabetes Mellitus, Type 1; Diabetic Ketoacido | 2011 |
Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs.
Topics: 3-Hydroxybutyric Acid; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 1; Disease Mo | 2010 |
Diagnosis of fulminant type 1 diabetes mellitus in an autopsy case with postmortem changes.
Topics: 3-Hydroxybutyric Acid; Adult; Autopsy; Body Fluids; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis | 2011 |
Measurement of β-hydroxybutyrate in cats with nonketotic diabetes mellitus, diabetic ketosis, and diabetic ketoacidosis.
Topics: 3-Hydroxybutyric Acid; Animals; Cat Diseases; Cats; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis | 2012 |
Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Amino Acids; Bicarbonates; Blood Glucose; Case-Control Studies; Diabet | 2012 |
GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy.
Topics: 3-Hydroxybutyric Acid; Aged; Animals; Cell Line; Chemokine CCL2; Diabetes Mellitus, Experimental; Di | 2012 |
Point-of-care β-hydroxybutyrate measurement for the diagnosis of feline diabetic ketoacidaemia.
Topics: 3-Hydroxybutyric Acid; Animals; Cat Diseases; Cats; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis | 2012 |
Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children.
Topics: 3-Hydroxybutyric Acid; Adolescent; Autoantibodies; Autoimmunity; Blood Glucose; Child; Child, Presch | 2013 |
3-Hydroxybutyric acid interacts with lipid monolayers at concentrations that impair consciousness.
Topics: 1,2-Dipalmitoylphosphatidylcholine; 3-Hydroxybutyric Acid; Anesthetics; Cell Membrane; Consciousness | 2013 |
The effect of walking before and after breakfast on blood glucose levels in patients with type 1 diabetes treated with intensive insulin therapy.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type | 2002 |
Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: no evidence for protective adaptation by the blood brain barrier.
Topics: 3-Hydroxybutyric Acid; Acute Disease; Adaptation, Physiological; Animals; Blood-Brain Barrier; Brain | 2002 |
Cost effectiveness of the direct measurement of 3-beta-hydroxybutyrate in the management of diabetic ketoacidosis in children.
Topics: 3-Hydroxybutyric Acid; Child; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Diabetic Ketoacidosi | 2003 |
Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients.
Topics: 3-Hydroxybutyric Acid; Adult; Age of Onset; Blood Glucose; Blood Specimen Collection; C-Peptide; Cap | 2003 |
Shift in metabolic substrate uptake by the heart during development of alloxan-induced diabetes.
Topics: 3-Hydroxybutyric Acid; Alloxan; Animals; Blood Glucose; Blood Pressure; Body Weight; Carbon Dioxide; | 2003 |
What are capillary blood ketone levels in type 1 diabetic patients using CSII in normal conditions of insulin delivery?
Topics: 3-Hydroxybutyric Acid; Blood Glucose Self-Monitoring; Body Mass Index; Capillaries; Diabetes Mellitu | 2004 |
Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study).
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Blood Glucose; Child; Child, Preschool; Diabetes M | 2006 |
Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes.
Topics: 2,4-Dinitrophenol; 3-Hydroxybutyric Acid; Acetyl-CoA Carboxylase; Acetylcysteine; AMP-Activated Prot | 2007 |
[Blood glucose and ketone monitoring in type 1 diabetic patients in the controlled environment of a summer camp].
Topics: 3-Hydroxybutyric Acid; Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 1; | 2007 |
Cardiac troponin I concentrations in people presenting with diabetic ketoacidosis.
Topics: 3-Hydroxybutyric Acid; Adult; Aged; Biomarkers; Cohort Studies; Creatine Kinase; Cystatin C; Cystati | 2007 |
Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Bicarbonates; Biomarkers; Blood Glucose; Child; Diabetes M | 2008 |
Angiotensin-converting enzyme in diabetes mellitus dependence on metabolic aberration.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Blood Glucose; Carbon Dioxide; Diabetes Mellitus, Ty | 1983 |
Responses to continuous and intermittent exercise in healthy and insulin-dependent diabetic children.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Blood Glucose; Butyrates; Child; Diabetes Mellitus | 1983 |
Impaired insulin action in newly diagnosed type 1 (insulin-dependent) diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 1; Erythrocytes; Fatty Acids, Nonesterified; F | 1984 |
The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glycerol; H | 1984 |
Ketone body kinetics in humans: the effects of insulin-dependent diabetes, obesity, and starvation.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Adult; Diabetes Mellitus, Type 1; Diabetic Ketoaci | 1984 |
Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adult; Amino Acids; Diabetes Mellitus, Type 1; Diabet | 1984 |
Management of third-trimester diabetic pregnancies with the use of continuous subcutaneous insulin infusion therapy: a pilot study.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 1; Female; Humans; Hydroxybutyrates; I | 1984 |
Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Awareness; Blood Glucose; Diabetes Mellitus, Type 1; Epine | 1994 |
Hormonal, metabolic, and circulatory responses to insulin-induced hypoglycemia in pregnant and nonpregnant women with insulin-dependent diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Circulation; Blood Glucose; Blood Pressure; Catecholamines; Diab | 1994 |
Hypoglycemia-induced autonomic failure in IDDM is specific for stimulus of hypoglycemia and is not attributable to prior autonomic activation.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Analysis of Variance; Autonomic Nervous System; Blood Glucose | 1994 |
Exaggerated epinephrine response to hypoglycemia in a physically fit, well-controlled IDDM subject.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 1; E | 1994 |
Hepatic glucose production during intraperitoneal and intravenous closed-loop insulin regulation of blood glucose in type 1 (insulin-dependent) diabetic patients.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Fatty Acids, None | 1993 |
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Brain; Cognition; Diabetes Mellitus, Type 1; Female; Glycerol | 1993 |
Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Adult; Age Factors; C-Peptide; Child; Circadian Rh | 1993 |
Polymorphonuclear cell-mediated phagocytosis and superoxide anion release in insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Candida albicans; Cells, Cultured; Diabetes Mellitus, Type | 1993 |
Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Blood Pressure; Cognition; Diabetes Mellitus, Type 1; D | 1993 |
Ketosis is involved in the origin of prurigo pigmentosa.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Diabetes Mellitus, Type 1; Feeding and Eating Disorders; F | 1996 |
Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Drug Adm | 1995 |
Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Diabetes Mellitus, Type 1; Epinephrine; Fatty | 1996 |
Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Analysis of Variance; Blood Glucose; C-Peptide; Diabetes Mell | 1996 |
Cardiovascular, metabolic, and hormonal responses to noradrenaline in diabetic patients with autonomic neuropathy.
Topics: 3-Hydroxybutyric Acid; Adrenergic alpha-Agonists; Adult; Blood Glucose; Blood Pressure; Cardiac Outp | 1996 |
Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: evidence for a nonselective defect.
Topics: 3-Hydroxybutyric Acid; Autonomic Nervous System Diseases; Blood Glucose; Carbon Dioxide; Diabetes Me | 1997 |
Lipolytic responsiveness to epinephrine in nondiabetic and diabetic humans.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Carbon Radioisotopes; Diabetes Mellitus, Typ | 1997 |
Alcoholic ketoacidosis at autopsy.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adolescent; Adult; Aged; Aged, 80 and over; Alcoholis | 1998 |
The Diabetes in Early Pregnancy Study: beta-hydroxybutyrate levels in type 1 diabetic pregnancy compared with normal pregnancy. NICHD-Diabetes in Early Pregnancy Study Group (DIEP). National Institute of Child Health and Development.
Topics: 3-Hydroxybutyric Acid; Abortion, Spontaneous; Adult; Cohort Studies; Diabetes Mellitus, Type 1; Fast | 1998 |
Serum leptin levels in young females with insulin-dependent diabetes and the relationship to hyperandrogenicity and microalbuminuria.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Albuminuria; Blood Pressure; Body Mass Index; Chromatograp | 1998 |
MCT/LCT emulsion ameliorate liver fat deposition in insulin-treated diabetic rats receiving total parenteral nutrition.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabete | 1998 |
Effect of hyperketonemia on plasma lipid peroxidation levels in diabetic patients.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Child; Diabetes Mellitus; Diabetes Mellitus, Type 1; Di | 1999 |
Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes.
Topics: 3-Hydroxybutyric Acid; Animals; Animals, Newborn; Blood Glucose; Diabetes Mellitus, Type 1; Gene Exp | 2000 |
Low-dose IGF-I has no selective advantage over insulin in regulating glucose metabolism in hyperglycemic depancreatized dogs.
Topics: 3-Hydroxybutyric Acid; Alanine; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Typ | 2001 |
The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Bicarbonates; Blood Glucose; Diabetes Mellitus, Type | 2001 |
Effect of near physiologic insulin therapy on hypoglycemia counterregulation in type-1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Fatty Acids, None | 2001 |
Hyperketonemia increases tumor necrosis factor-alpha secretion in cultured U937 monocytes and Type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetylcysteine; Antioxidants; Cyclic AMP; Diabetes Mellitus, T | 2002 |
Lack of feedback inhibition of insulin secretion in denervated human pancreas.
Topics: 3-Hydroxybutyric Acid; Adult; Analysis of Variance; Blood Glucose; C-Peptide; Denervation; Diabetes | 1992 |
What if Minkowski had been ageusic? An alternative angle on diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 1; Diab | 1992 |
Absence of the dawn phenomenon and abnormal lipolysis in type 1 (insulin-dependent) diabetic patients with chronic growth hormone deficiency.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; E | 1992 |
The ketosis-resistance in fibro-calculous-pancreatic-diabetes. 1. Clinical observations and endocrine-metabolic measurements during oral glucose tolerance test.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mel | 1992 |
Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 1; Drug A | 1992 |
Impact of increased growth hormone secretion on carbohydrate metabolism in adolescents with diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Carbohydrate Metabolism; Carrier Proteins; Child; Diabetes Mellit | 1991 |
Serum ketone response to glucagon as a marker of insulin dependency in diabetics.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus | 1991 |
Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Fatty Ac | 1991 |
The effect of insulin withdrawal on intermediary metabolism in patients with diabetes secondary to chronic pancreatitis.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 1; Epinephrine | 1991 |
Secretion of triglyceride and ketogenesis by livers from spontaneous diabetic BB Wistar rats.
Topics: 3-Hydroxybutyric Acid; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; | 1991 |
Effects of insulin deprivation and replacement on in vivo subcutaneous adipose tissue substrate metabolism in humans.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Dialysis; Ep | 1991 |
Diurnal variation of blood ketone bodies in insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus patients: the relationship to serum C-peptide immunoreactivity and free insulin.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes | 1990 |
Effect of phase of menstrual cycle on insulin sensitivity, peripheral blood flow and cardiovascular responses to hyperinsulinaemia in young women with type 1 diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 1; Female; Fore | 1990 |
Increased lipolytic sensitivity to catecholamines in diabetic patients with severe autonomic neuropathy.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adult; Autonomic Nervous System Diseases; Blood Glucose; Cate | 1990 |
Failure of nocturnal hypoglycemia to cause daytime hyperglycemia in patients with IDDM.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; E | 1990 |
Substrate metabolism during modest hyperinsulinemia in response to isolated hyperketonemia in insulin-dependent diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 1; Gluconeogenesis; Glucose; Glycerol; Hormone | 1990 |
Lack of effects of hyperglycemia on the disposal of 3-hydroxybutyrate in insulin-dependent diabetic patients.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Fatty Acids, | 1990 |
Substrate availability other than glucose in the brain during euglycemia and insulin-induced hypoglycemia in dogs.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Blood Glucose; Brain; Diabetes Mellitus, Experimental | 1990 |
Inability to stimulate skeletal muscle or whole body protein synthesis in type 1 (insulin-dependent) diabetic patients by insulin-plus-glucose during amino acid infusion: studies of incorporation and turnover of tracer L-[1-13C]leucine.
Topics: 3-Hydroxybutyric Acid; Amino Acids; Blood Glucose; Carbon Isotopes; Diabetes Mellitus, Type 1; Gluca | 1990 |
Effects of pancreas transplantation on metabolic and hormonal profiles in IDDM patients.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Circadian Rhythm; Creatinine; Diabetes Mellitus, Type 1 | 1989 |
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetic Neuropat | 1989 |
Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dep
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Humans; Hy | 1989 |
Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children.
Topics: 3-Hydroxybutyric Acid; Adolescent; Amino Acids; Blood Glucose; Child; Child, Preschool; Diabetes Mel | 1989 |
Reversal of insulin resistance in type 1 diabetes following initiation of insulin treatment.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Female; Growth Ho | 1986 |
Hyperglycemia after intense exercise in IDDM subjects during continuous subcutaneous insulin infusion.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Female; | 1988 |
Neutrophil phagocytosis and killing in insulin-dependent diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Aldehyde Reductase; Candida albicans; Cells, Culture | 1986 |
Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis.
Topics: 3-Hydroxybutyric Acid; Adult; Bicarbonates; Blood; Blood Glucose; Chlorides; Diabetes Mellitus, Type | 1988 |
Glucagon, not insulin, may play a secondary role in defense against hypoglycemia during exercise.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 1; Epi | 1988 |
Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate.
Topics: 3-Hydroxybutyric Acid; Adult; Albuminuria; beta 2-Microglobulin; Blood Glucose; Diabetes Mellitus, T | 1987 |
The metabolic response to insulin deprivation in idiopathic brittle diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Epinephrine; Fat | 1986 |
Effect of insulin on growth hormone-induced metabolic derangements in diabetes.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Fatty Acids, Non | 1986 |
Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, | 1985 |
The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins.
Topics: 3-Hydroxybutyric Acid; Absorption; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Food; Hu | 1985 |
The metabolic response to the euglycemic insulin clamp in type I diabetes and normal humans.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Diabetes Mellitus, Type 1; Fasting; Fatty Acid | 1985 |
Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Blood Glucose; Diabetes Mellitus, Type 1; Fatty Acids, Nonest | 1985 |
The effect of insulin deprivation on fasting levels of 5000 dalton gastric inhibitory polypeptide in type 1 (insulin-dependent) diabetics.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Fasting; Gastric Inhibitory | 1985 |
Ketone body production and disposal in diabetic ketosis. A comparison with fasting ketosis.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acidosis; Adolescent; Adult; Diabetes Mellitus, Type 1; Diabet | 1985 |
Acetoacetate and 3-hydroxybutyrate kinetics in obese and insulin-dependent diabetic humans.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetic | 1985 |
Metabolic control of type I (insulin dependent) diabetes after pancreas transplantation.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glucagon; Humans; Hy | 1985 |
Ketone body metabolism in normal and diabetic human skeletal muscle.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Carbon Radioisotopes; Diabetes Mellitus; Diabetes Melli | 1985 |